Artificial Intelligence is gradually infiltrating people's lives, and the healthcare industry has also changed a lot, with AI+medicine emerging rapidly in recent years. So, what is AI+ medical?
Artificial Intelligence + medical, is the phenomenon of the empowerment of AI technology on the application scenarios of medical-related fields, that is, the use of state-of-the-art AI technology, to achieve the informationization between patients and healthcare workers, healthcare institutions and medical equipment. It can be understood as the application of AI technology and big data services to the medical industry through the construction of infrastructure and data collection, to improve the diagnostic efficiency and service quality of the medical industry, and to better solve the problems of shortage of medical resources and aging population.
Policy support, technology iteration coupled with market demand to promote, AI + medical ushered in the rapid development
2020, is the turning point of the AI + medical industry. On the one hand, the AI medical three types of devices through the review, so that the AI medical imaging industry ran through the review and approval stage plagued by its years, from the "application of landing" into the "commercialization"; on the other hand, the epidemic accelerated hospitals and enterprises to carry out active intelligent reconstruction. According to Ai Rui "China AI + medical industry research report" speculation, 2020-2022 CAGR (compound growth rate) will reach 51.9%, 2022 is expected to AI + medical market size will be more than 7 billion yuan.
In addition the policy dividend, also greatly promote the application of AI + medical practice landing.
AI+ medical track is on fire, and the amount of financing obtained so far in 2020 is nearly 20 billion RMB
According to the data of the China Business Industry Research Institute, in 2020, AI+ medical has accounted for 18.9% of the artificial intelligence market. Also according to IDC statistics, the total value of the AI application market will reach $127 billion by 2025, of which the application of AI in the healthcare industry will account for one-fifth of the market size, or $25 billion. Of all the applications of AI, healthcare ranks first.
AI+ medical imaging products and enterprises continue to emerge, according to the incomplete statistics of the eye of the sky check, 2020 so far, the domestic AI+ medical field *** occurred 89 financing events, the financing amount reached a total of 17.5 billion yuan yuan, of which medical imaging accounts for about 1/3 of the total number of financings.
Eye of the sky check the Data Research Institute found that from the financing rounds in the past two years, the number of rounds of financing. More than 60% of enterprises in the A round and B round, this part of the enterprise began to enter the mature stage of development, the product technology has been recognized by the market, the business model tends to mature enterprise is also more likely to get the favor of the capital. The company has also increased its technology research and development efforts, and has been able to accelerate the pace of development through innovation and competitive advantage.
AI+Medical Application Scenarios
At present, China's AI+Medical is mainly used in medical imaging, auxiliary medical care, drug research and development, health management, disease prediction and other five major fields.
AI medical imaging. Characterized by fast speed, high stability and low cost. With the development of medical imaging big data and image recognition technology, medical imaging has become one of the most mature areas of the combination of artificial intelligence and healthcare in China. the AI medical imaging industry has a bright performance, and there are already mature products in the field of tuberculosis, fundus, breast cancer, and cervical cancer.
Eyeball data shows that there are currently more than 20,000 companies in China with business names or scopes of operation that include "medical imaging, medical imaging" in business, surviving, moving in and out of the relevant enterprises, and more than 50 percent of the relevant enterprises were established within five years. In terms of geographic distribution, Guangdong has the largest number of medical imaging-related companies, with more than 3,000, accounting for 13% of the country.
The combination of artificial intelligence and healthcare has iterated traditional healthcare into the era of smart healthcare, and the ability of artificial intelligence (AI) medical imaging to aid in diagnosis is becoming more and more apparent. From the point of view of patent application data, 2011-2020 patent application information*** counted more than 7,000 pieces, and the number is rising year by year. Among the types of patents, invention patents account for the largest proportion, reaching 53.73%, followed by utility models, accounting for 38.46%.
AI-assisted medical treatment. In terms of assisted diagnosis, taking the Watson doctor platform as an example, it can synthesize all kinds of information about the patient in a short time, combined with millions of information to give accurate diagnostic results and treatment plans. In terms of assisted surgery, take the da Vinci robot as an example, this is a human-robot collaboration robot, in the process of surgery, the doctor can be thousands of miles away to use the robotic arm real-time, accurate surgical assistance.
China currently has more than 110,000 medical diagnostic-related enterprises, more than 80% of the relevant enterprises were established within five years, of which, only in 2020, more than 30,000 new enterprises registered, with a growth rate of 63%. From a geographical distribution point of view, Guangdong has the largest number of AI-assisted diagnostic enterprises, with more than 30,000, accounting for 30% of the country.
AI drug development. Domestic new drug development is still dominated by generic and improved drugs, mainly for the cooperation between AI companies and pharmaceutical companies to develop new drugs. The complete drug development process includes target screening, drug discovery, and clinical trials. With the application of big data and artificial intelligence in scientific research, drug research and development will become more precise and convenient, efficiently solving the problems of long cycle, high cost and low success rate.
China currently has more than 60,000 drug research and development-related enterprises, 50 percent of the relevant enterprises were established within 1 year, of which, only in 2020, more than 20,000 new enterprises registered, with a growth rate of nearly 100%. From a geographical distribution point of view, Guangdong has the largest number of AI drug R&D enterprises, with more than 11,000, accounting for 18% of the country.
AI health management. The product form is mainly intelligent wearable devices. 2019 medical AI scope expanded to the scope of recreation, the wide application of domestic wearable devices in the medical scene, through the intelligent analysis of health big data, can help individuals or enterprises targeted management of health, through a long period of real-time monitoring as well as data multi-dimensional management and analysis of passive disease treatment into active health monitoring.
China has more than 15,000 wearable device-related enterprises, of which 368 are high-tech enterprises, accounting for 2.4%. In terms of geographical distribution, Guangdong has the largest number of wearable device-related enterprises, with more than 12,000 enterprises. From the patent distribution point of view, the patent types of wearable device-related enterprises are mainly inventions, accounting for 46.2%, in addition, utility model and design patents accounted for 34.0% and 19.8% respectively.
AI disease detection. Mainly focuses on the field of genetic testing. Advantages: for one thing, China has a large number of data samples. Computers need a large amount of data to constantly train algorithms, and many countries do not have such a large population base, and the amount of data on diseases is limited; second, China has a wide range of application scenarios. A large number of patients, relatively few doctors, remote and artificial intelligence diagnosis in China has a large demand.
China currently has more than 5,800 genetic testing-related enterprises, of which 190 are high-tech enterprises, accounting for 3.2%. In terms of geographical distribution, Guangdong has the largest number of genetic testing-related enterprises, with nearly 1,300, accounting for 22%. In terms of patent distribution, the patent types of gene testing-related enterprises are mainly inventions, accounting for 72.4%, in addition, utility model and design patents accounted for 24.41% and 3.19% respectively.
The technology and application of dual-engine drive AI + medical empowerment of intelligent life is close at hand
From the AI + medical industry development trend, with the development of artificial intelligence, mobile Internet, Internet of Things, big data and big data security and other technologies, the health of the whole process of management of all aspects of the more and more intelligent, precision medicine will be more and more personalized, individualized. The first step is to make sure that you have the right tools for the job, and that you have the right tools for the job.
First of all, AI and big data in the medical industry intelligence, the establishment of manageable, controllable, traceable health medical data open operation system, to promote the circulation of medical and health data services, need to explore the medical data in the privacy of the computing and artificial intelligence and other new technologies based on the integration of innovative applications for the field of auxiliary diagnosis and treatment of the health care industry, in the privacy of the computing technology empowered to do so. privacy protection of medical data in the true sense of the word, and then maximize the release of data value. For example, China Controls Clear Channel, which focuses on privacy protection and data circulation technology, has already trained and analyzed AI models on medical image data and verified the consistency of the training results with the plaintext results.
Secondly, the maturity of the application of AI in the medical field, medical imaging, as a popular track for investment and financing in the field of AI+medical, is also becoming more and more subdivided in terms of application scenarios. The domestic application of AI + CT imaging in intelligent assisted diagnosis of cardiovascular diseases, neurological diseases, brain diseases, fundus diseases, lung diseases, etc. are more mature. For example: the pension enterprise fusion introduction of AI fundus screening, millimeter wave radar, high sensitivity biochip technology, for the elderly to create fundus artificial intelligence chronic disease detector and other black science and technology suitable for the elderly products, through the fundus detector 3 minutes to screen out 30 kinds of health diseases, to get the physical examination report based on the automatic algorithm generation.
In the future, by virtue of the excellent algorithms and big data analysis of AI+ healthcare, the data barriers of the various service ports of the relevant service platforms will gradually be opened up to realize the perfect landing of the core application scenarios, which will ultimately enhance the overall level of medical care in China.